Conestat alfa for the treatment of angioedema attacks

Benjamin Davis1, Jonathan A Bernstein

  • 1University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Immunology/Allergy Section, Cincinnati, OH, USA.

Insights

New treatments for hereditary angioedema (HAE) include conestat alfa, a C1 inhibitor replacement. Derived from transgenic rabbits, it offers a safe and effective alternative for acute HAE attacks.

Area of Science:

  • Immunology
  • Pharmacology
  • Genetics

Background:

  • Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent swelling attacks.
  • Current treatments for HAE involve C1 inhibitor (C1-INH) replacement therapies, with several new products recently approved.
  • Plasma-derived C1-INH products carry a risk of infectious transmission.

Purpose of the Study:

  • To review hereditary angioedema (HAE) and its treatment options.
  • To focus on the bench-to-bedside development and clinical trial findings of conestat alfa, a novel C1-INH replacement therapy.

Main Methods:

  • Review of existing literature on HAE and C1-INH replacement therapies.
  • Analysis of preclinical and clinical trial data for conestat alfa.
  • Comparison of conestat alfa with existing HAE treatments.

Main Results:

  • Conestat alfa is a novel C1-INH replacement produced from transgenic rabbits, offering a potentially unlimited and safer source compared to plasma-derived products.
  • Clinical trial data demonstrate that conestat alfa is safe and effective for treating acute HAE attacks.
  • The unique production method eliminates concerns regarding infectious transmission associated with human plasma-derived therapies.

Conclusions:

  • Conestat alfa represents a significant advancement in HAE treatment.
  • Its rabbit-derived origin provides a distinct advantage in terms of supply and safety.
  • Conestat alfa is a safe and effective therapeutic option for patients experiencing acute HAE attacks.

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...